Import & Export from/to Thailand

Author: Tavatchai Boodin (Page 1 of 2)

Cannabis and Hemp Business Guide – Thailand


Until June 9, 2022, cannabis and hemp had been classified as a category 5 narcotic under Thailand’s 1979 Narcotics Act. For many years, all activities related to the plants and their derivatives was heavily restricted until regulatory liberalization began in February 2019 with an amendment to the Narcotics Act. Over the next few years, restrictions on specific types or uses of cannabis and hemp were gradually loosened, and then Thailand became the first country in Asia to permit growing, selling, and using the plant for both medical and other permitted purposes when it delisted both cannabis and hemp plants and their unprocessed parts from the Narcotics Code on June 9, 2022.

This delisting now allows the private sector to grow, possess, sell, and use locally cultivated cannabis and hemp plants without a license. However, the Narcotics Code still regulates cannabis and hemp extracts containing tetrahydrocannabinol (THC) of more than 0.2%. Making or handling a substance with THC over this limit still requires a license, with limited exceptions.

However, the breadth of this liberalization will likely be tempered in the future. The draft Cannabis and Hemp Act, an omnibus law currently under the Thai Parliament’s consideration, is expected in the months to come. This act will specifically govern cannabis and hemp, including by imposing controls such as new restrictions or an enhanced licensing regime.

Most of the product classifications discussed here are based upon THC content, and on the presence of cannabidiol (CBD) in the products. As THC is considered a psychoactive substance—in comparison to CBD, which is not psychotropic and has been applied in various therapeutic indications—a higher THC content may therefore be associated with a greater risk of abuse, and thus stricter regulations will likely apply in Thailand. Under the most recent legal amendments, Thai law defines cannabis as in the Cannabis sativa L. subsp. indica, and hemp as Cannabis sativa L. subsp. sativa with no more than 1.0 % THC by dry weight in its leaves and inflorescence.

The key regulatory body for cannabis and hemp-related products is the Thai Food and Drug Administration (Thai FDA), a government agency operating under supervision of the Ministry of Public Health. Working closely with the Narcotics Control Committee, the Thai FDA is mainly responsible for granting and administering licenses and post-marketing control, among others. Representatives of the Thai FDA also sit on most of the national policymaking committees. One of the other Thai government bodies involved in the regulation and control of cannabis and hemp is the Department of Agriculture (under the Ministry of Agriculture and Cooperatives), which administers the rules on the importation of plant seeds (e.g., cannabis and hemp seeds).


Product Classification

Activity-Focused Regulatory Overviews

Cultivating Cannabis/Hemp

Following their June 9, 2022, delisting, Thai nationals may freely cultivate cannabis and hemp plants and trade unprocessed plant parts and crude resins in Thailand without a license.

As stated earlier, however, the current breadth of this liberalization is expected to be temporary. Upon promulgation of the current draft Cannabis and Hemp Act, the industry is likely to face new restrictions and an enhanced licensing regime.

Companies and importation activities are subject to various regulations. For companies, agricultural activities (including growing cannabis/hemp) are still reserved for majority Thai-owned companies.

Importation of cannabis/hemp plants and most unprocessed parts is still prohibited, except for cannabis/hemp seeds, which may be imported under the rules and procedures of the Plant Act (1975) and Plant Quarantine Act (1964).

Producing or Importing Cannabis/Hemp Extracts and Seed Oils

Industrial extraction of cannabis or hemp still requires a Thai FDA license under the Narcotics Code.

After the June 9, 2022, delisting, the following products are now deregulated:

  • Extracts containing 0.2% or less THC by weight produced from domestically grown plants and under license from the Thai FDA, and
  • Seed oils produced from domestically grown seeds.

These deregulated products may be sold, possessed and consumed without a license under the Narcotics Code. Howver, handling any extract or oil that does not fall within the conditions set out above requires a license from the Thai FDA under the Narcotics Code.

Importation. Importation of any extract or oil is still prohibited.

Producing or Importing Medical Cannabis/Hemp and Other Herbal Products

Production. Irrespective of THC content, medical cannabis/hemp (including Thai traditional medicines and cannabis oils) and other herbal products (including herbal cosmeceuticals and nutraceuticals) now fall under the purview of the Herbal Product Act (2019). The act, along with its subsequent implementing regulations, provides licensing and product registration requirements for domestic production and distribution of these products.

Importation. Importation of these products is still largely prohibited with a few exceptions: Thai government agencies importing goods for treatment of patients, public academic institutions importing for research purposes, and anyone importing for human clinical trials, subject to the licensing procedures of the Thai FDA under the Herbal Products Act.

Producing or Importing Modern Drugs Formulated with Cannabinoids

Modern drugs formulated with cannabis, hemp extract, or other cannabinoids require regulatory review and licensing from the Thai FDA under the Drug Act. The licensing rules and procedures are already in place through existing ministerial regulations and notifications. Notably, a drug manufacturer or importer license is required for the business operator, and a drug registration certificate is required to market a particular modern drug formulation.

Producing or Importing Cosmetics with Hemp- and Cannabis-based Ingredients

Production. Domestically produced cosmetics may contain any or combination of hemp seed oils, hemp seed extracts, parts of hemp (except inflorescence), parts of cannabis (except inflorescence and seeds), and CBD extracts, provided that the raw materials are obtained from plants grown in Thailand. The production requires a Thai FDA license under the Cosmetics Act. Additionally, the products themselves must comply with the specifications prescribed by the relevant ministerial notifications.

Cannabis seeds, cannabis seed oils, and inflorescences of cannabis and hemp, regardless of their origins, are prohibited from cosmetic product formulations.

Importation. Importation of cosmetic products containing hemp- or cannabis-based ingredients is still prohibited.

Producing or Importing Food, Beverages, Food Supplements, or Food Additives with Hemp- and Cannabis-based Ingredients

Production. Food products may contain hemp seeds, hemp seed oils, hemp seed proteins, parts of hemp (except inflorescence), parts of cannabis (except inflorescence and seeds), and CBD extracts, provided that these are obtained from plants grown in Thailand. For domestically produced goods, a Thai FDA license is required under the Food Act, and the product must comply with the relevant ministerial notifications.

While this allowance is applicable to many food products, there are exceptions. For example, no part of cannabis or hemp may be added to food for infants, food for young children, or energy drinks. In addition, certain foods do not allow addition of cannabis and hemp. Certain other foods allow use with conditions. Because of this variation in rules for different kinds of food, it is important to check the relevant regulations to ensure compliance.

Cannabis seeds, cannabis seed oils, and inflorescences of cannabis and hemp are not allowed as ingredients in any food product.

Importation. Importation of food products containing hemp- or cannabis-based ingredients is still prohibited—even if the cannabis- or hemp-based ingredients came from plants grown in Thailand.

Ready-to-Eat Foods and Beverages

Thai restaurants and cafés are allowed to use cannabis parts (except inflorescence and seeds) and hemp parts (except inflorescence) in their recipes.

Crop and processing infrastructure

The Cannabis and Hemp Act drafting committee is planning to organize cultivation into three classes. Small cultivators, with no more than 10 plants per household, may not have to pay fees but will have to notify the Thai FDA of their growing activities. Medium cultivators, with less than 32,000 square meters (<20 rai) under cultivation, will have to go through additional bureaucratic procedures and pay additional fees. Large cultivators, with over 32,000 square meters (>20 Rai) under cultivation, will be considered commercial cultivators and require FDA approval. Fees for large cultivators are likely to include both monthly and annual payments.

The committee has decided that modern medical practice and traditional physicians, and other healthcare professionals cultivating cannabis for medical purposes, will only be required to notify the FDA of their activities (similar to the requirements for small cultivators).

The Narcotics Division of the Thai FDA published handbooks on growing and handling cannabis crops in 2021. Cultivators can choose among outdoor, semi-outdoor, and indoor cultivation. Outdoor cultivation is described as being low-cost and suitable for Thai cannabis varieties, with the drawbacks of limited pest-control options and harvesting taking place annually. On the other hand, indoor cultivation comes with higher costs but with the advantages of better quality control and year-round harvesting. As for the import of cultivation and processing infrastructure, such as equipment for crop maintenance, testing, extraction, formulation, and packaging, relevant regulations are in place and need to be considered.

Intellectual Property


On January 28, 2019, the Thai government issued an ordinance to reject a number of Thai patent applications filed by foreign applicants, all of which related to medical formulation or use of cannabis-derived active ingredients. The ordinance was issued to annul any private exclusive rights that could block access to medical cannabis following its legalization, and it was terminated on February 19, 2019, when cannabis legalization took effect. Since then, patentability has once again been examined against the previously established rules of the Patents Act. This means that generally, an application related to cannabis is eligible for a patent if it is not for recreational purposes; not a diagnostic or therapeutic method; and not the plant itself, its part, or crude extract.


Generally, trademark protection for goods or services related to legalized use of cannabis or hemp is available in Thailand, as long as the trademark meets the usual requirements for registration.

Key Dates

April 28, 1979 The Narcotics Act (No. 1) took effect, declaring cannabis and hemp category 5 narcotics.
January 1, 2018 The Hemp Regulation RE: Application of the License and Issuing of Licenses to Manufacture, Disposal or Possession of Hemp came into effect, allowing cultivation and processing of hemp only for industrial such as textiles, paper industries, etc. or non-commercial uses, such as consumption by indigenous groups or research and development. Nonetheless during 2018 until January 29, 2021, only state agencies were able to obtain the licenses in relation to hemp.
Janurary 28, 2019 The National Council for Peace and Order’s Ordinance No. 1/2562 became effective, rejecting Thai patent applications related to cannabis (see also Intellectual Property, above).
February 19, 2019  The Narcotics Act amendment (No. 7) came into effect, legalizing medical use of substances listed as category 5 narcotics (e.g., cannabis, hemp, and kratom).
March 30, 2019  A ministerial notification took effect setting out 16 cannabis-containing Thai traditional medicine formulations that may be consumed for therapeutic purposes without having to be registered with the Thai FDA, as long as manufacturers obtain a narcotic production license from the Thai FDA [overridden by the Key Event of June 9, 2022, below].
May 21, 2019 End of the “amnesty period,” during which persons possessing cannabis for certain purposes (medical, research, etc.) could declare their possession to the Thai FDA and be exempted from criminal punishment.
August 7, 2019 The Government Pharmaceutical Organization launched the first batch of medical CBD oil, THC oil, and CBD: THC oil (4,500 units of 5 milliliters each) for the special access scheme (SAS) in public hospitals.
February 15, 2020 The Minister of Public Health updated the list of cannabis-containing Thai traditional medicine formulations that may be consumed for therapeutic purposes and/or research purposes, without having to be registered with the Thai FDA [overridden by the Key Event of June 9, 2022, below].
December 14, 2020 The “delisting” ministerial notification became effective, carving out domestically produced items containing certain cannabis and hemp plant parts, and CBD extract with less than 0.2% THC by weight, from the scope of Narcotics Act (see also Product Classification, above). Importation of these products still requires an importation license as prescribed in the Narcotics Act [overridden by the Key Event of June 9, 2022, below].
January 29, 2021 The Hemp Regulation RE: Application of the License and Issuing of Licenses to Manufacture, Import, Export Disposal or Possession of Hemp took effect, allowing cultivation for production of modern drugs, herbal products, cosmetics, and food products, as well as for household and certain other uses. This allowed hemp to be used in healthcare- related products. Private entities established in Thailand and groups of farmers (e.g., cooperatives or community enterprises) can obtain licenses without forming a partnership with a state agency.
June 4, 2021 Eight herbal formulas containing cannabis as an active ingredient are listed in the National List of Essential Drugs, which identifies both modern drugs and herbal products deemed necessary for the prevention and treatment of major health problems in Thailand. It also provides a drug reimbursement mechanism for government hospitals.
August 11, 2021 Cannabis and hemp seeds become controlled seeds under the Plants Act (1975). The seeds must exhibit at least 70 percent germination and 99 percent purity. Licensed traders (i.e., importers, collectors) must follow the requirements prescribed in the Plants Act and its bylaws.
August 24, 2021 Kratom is removed from the list of category 5 narcotics, (some parts of cannabis and hemp plants and their derivative products remain on the list—see December 14, 2020).
October 25, 2021 Cannabis L. genus is recognized as eligible for protection as a new plant variety under the Plant Variety Protection Act (1999).
November 26, 2021 The Cannabis Regulation RE: Application of the License and Issuing of Licenses to Manufacture, Import, Export, Dispose or Possession of Cannabis takes effect.
December 9, 2021 The Narcotics Code becomes effective, replacing and consolidating the previous Narcotics Act and Psychotropic Substances Act, among others. The Narcotics Code has transitional provisions that maintain the effects of regulations and validity of licenses previously issued under the Narcotics Act.
June 9, 2022 Cannabis and hemp plants are delisted from the Narcotics Code. Thai nationals may grow the plant and handle unprocessed parts without a license. However, extracts and seed oils remain governed by the Narcotics Code. Finished products may contain cannabis or hemp under the regulation of their respective laws.
June 16, 2022 The Minister of Public Health issues an official notification under the Act on Protection and Promotion of the Knowledge on Thai Traditional Medicines (1999). The notification prohibits selling cannabis to minors (under the age of 20), use of cannabis by pregnant and breastfeeding women, and smoking cannabis in public.
Forthcoming The Cannabis and Hemp Act will likely institute new restrictions and an enhanced licensing regime.


© 2021 Tilleke & Gibbins International Ltd.

Thailand – Recent TFDA updates

Due to the increased hygiene precautions from the COVID-19 pandemic, alcohol-based hand sanitizers and disposable medical face masks are facing severe shortages in Thailand. The Thai government has enacted several regulations to try to abate the shortage. The Ministry of Public Health (MOPH) has relaxed some regulations on the importation and production of these goods. In addition, the Department of Internal Trade of the Ministry of Commerce has acted to control the supply by setting up maximum allowable purchase price of domestic and imported face masks. Other regulations related to these products have been modified to counteract shortages—examples include reclassification of alcohol-based hand sanitizers, implementation of fast-track pathways for the domestic production of alcohol-based hand sanitizers, declaration of alcohol-based hand sanitizers and disposable medical masks as controlled goods, and so on. Regulations such as these will likely continue to change periodically, so healthcare entrepreneurs should check frequently that they are compliant with the latest updates.

Thailand’s Updated Regulations on Alcohol-Based Hand Sanitizers and Disposable Medical Masks

There have been three notable regulations pertaining to alcohol-based hand sanitizers. First, the MOPH has retracted its 2019 reclassification of alcohol-based hand sanitizers as medical devices (Medical Device Act B.E. 2251 (2008)), instead choosing to continue to categorize it as a cosmetics product (Cosmetics Act B.E. 2558 (2015)). The MOPH’s decision to cancel the reclassification serves to alleviate the shortage of alcohol-based hand sanitizers because the more stringent controls of medical devices would cause further delays in restocking. The second regulation enforces a minimum alcohol concentration of 65% w/w in alcohol-based hand sanitizers in order to gain registration as a controlled cosmetic. Finally, the Thai Food and Drug Administration (FDA) has also relaxed regulations to allow domestic pharmaceutical manufacturers, traditional drug manufacturers, and medical device manufacturers to produce and sell alcohol-based sanitizer without first obtaining a cosmetics manufacturing license.

The shortage of disposable face masks is much more acute than sanitizers. Hospitals have run out due to high public demand, low production scale, and consumer hoarding. People have taken advantage of the opportunities to gain additional income by making and selling masks as an alternative to commercial grade face masks. However, these homemade, reusable masks are not classified as medical devices and therefore, cannot be advertised as personal protective equipment against COVID-19. Only disposable medical masks, which are classified as low-risk medical devices, are regulated. Imported masks require product registration with the Thai FDA. Because of the pandemic, the Medical Device Control Division has agreed to facilitate all registration of disposable medical masks.

Price Controls

As both alcohol-based sanitizer and disposable medical masks are currently in high demand, the Thai Central Committee on Prices of Goods and Services (CCP) has published price controls for these goods. The manufacturer, importer, and distributor of alcohol-based hand sanitizer are required to give the CCP their pricing details and may not increase the price without CCP’s permission. For domestically manufactured disposable medical masks, the retail price must not exceed THB 2.50 (approx. USD 0.08) per mask. Currently, the price of imported masks has not been fixed, and the CCP only requires that the importer, distributor, and retailer must not mark up the price more than 10%, 10%, or 23%, respectively. Because only domestic masks are regulated with a fixed price (and because some traders do not obey the law in such a high demand market), the price of masks in the Thai market continues to rise.


On February 19, 2019, by amending its 1979 Narcotics Act, Thailand became the first Asia-Pacific country to legalize medicinal cannabis. While hemp had been approved for use in industry since 2018, the amendment of the Narcotics Act providing for a Thai FDA registration pathway for medicinal cannabis, was largely unexpected.

While the amendments create the foundation for a cannabis industry in Thailand, the true viability and future of the Thai cannabis industry lies in its regulation by both the Thai FDA and the Narcotics Control Board. With the return of an elected government, a new cabinet was sworn in on July 16, 2019, with the Bhumjaithai Party appointed to oversee the Ministry of Public Health (MoPH). The Bhumjaithai Party campaigned on further expansion of liberal cannabis policies, which was well received by the public. With the minister in charge of instituting regulations that further define the scope and use of cannabis for medical purposes, we can only expect further liberalization and clarification.

Some recent clarification was seen by way of helpful MoPH notifications that identified forms of medical cannabis allowed for approved use. These include (i) registered drugs per the Drug Act; (ii) Thai traditional medicines having approved compositions (now 16 formulas); and (iii) drugs approved for Thailand’s Special Access Scheme. Also further clarified were the specific qualifications of Thai traditional practitioners having authority to prescribe traditional cannabis medicines.

Most recently, two additional notifications from the Narcotics Control Board were enacted concerning the labels of medical cannabis products, and the forms for recording inventory movements of medical cannabis.

The exact Thai FDA medical cannabis licensing pathway is to be set out in Implementing Regulations that have been circulated widely for both official and public comment. These are expected to be approved by the MoPH very soon. As the regulations look to move things forward—and the government wants exactly that—no significant change in the regulations is expected before they become law.

As the Narcotics Act and draft Implementing Regulations currently stand, a complex network of who can be licensed for what purposes seeks to ensure control over the process for the beginning stages. There are currently four types of licenses: (1) production, (2) importation/exportation, (3) sale, and (4) possession. There are currently seven entities under both the Narcotics Act and the draft Implementing Regulations who can apply for medical cannabis licenses: (1) public entities, (2) healthcare professionals, (3) private universities, (4) collective farmers, (5) international transportation agencies, (6) traveling patients, and (7) groups to be permitted by further decisions of the MoPH. A further seven entities are set out in the draft Implementing Regulations.

The draft Implementing Regulations also address which parties can engage in which activities. Certain licensed activities are available to some entities, but not to others. For example, a healthcare professional is ineligible for a license to possess cannabis for the purpose of addiction treatment, but can be licensed to possess cannabis for R&D purposes. Further clarification will come with promulgation of the draft, Implementing Regulations. The listing of successful Thai FDA license applicants on the Thai FDA website (as is the case with other Thai FDA regulated products such as human and animal pharmaceuticals, medical devices, food, cosmetics, and hazardous substances) will also provide more clarity.

Foreign participation in Thailand’s cannabis industry is severely restricted for the first five years, starting from February 19, 2019. During this period, only state agencies may obtain a license to produce, import or export cannabis. However, a private entity, with an office in Thailand and at least two-thirds of directors, partners, or shareholders having Thai nationality, may act jointly with a state agency to acquire or share these types of commercialization licenses. In this way, certain companies can be involved in the Thai cannabis industry from its inception. There are no restrictions requiring joint participation in R&D efforts (i.e., non-commercialization).

Fortunately, the Narcotics Act’s aforementioned allowance of new categories of entities (category 7 above) to acquire licenses as the MoPH sees fit is open-ended and, with a party that fought for liberal cannabis policies at the reins, promising. With a population currently in need of medicinal cannabis, the facilities established by the government might not be able to supply enough medical grade cannabis for the current need or to supply it quickly enough. This need for assistance may open the door for foreign entities to enter the market and provide access to enough medicinal cannabis to meet demand.

The current state of regulation provides three basic approaches for any foreign entity looking to enter the Thai cannabis industry. For most of the approaches, extensive work with government regulatory agencies and coordinating joint operations with state agencies will be needed.

The first approach is to import materials into Thailand. Getting the materials into Thailand, whether for distribution or for research & development, will be necessary in the near future as there are no materials to source within Thailand at the moment. This could mean as little as importing finished products ready for distribution, or as much as importing seeds, plants, supplies, personnel, facilities, or other necessities for production or research.

The second approach is to establish domestic manufacturing facilities for the production of cannabis and cannabinoid products. Establishing domestic production in Thailand would be beneficial for several reasons. First, Thailand has a long history of agricultural knowledge in cannabis production, and great facilities for R&D exist through research institutes such as universities and pharmaceutical companies. Second, Thai production comes at a low cost and is associated with a record of safe manufacturing practices for ingestible products. This can be done either by sourcing materials and personnel from within Thailand or by using what was imported in the first approach.

The third approach is to use Thailand as a headquarters for expansion into other Asia-Pacific regions, such as Laos, the next prospective country to follow Thailand’s lead in legalizing medicinal cannabis, or China. Depending on the business model, this could include using production facilities in Thailand to export products throughout Asia-Pacific, establishing networks in the region, or acting as an intermediary between producers and consumers.

Ban on trans fats comes into force on January 9, 2019

A vendor removes a (legal) deep-fried chicken from his wok. The ban on ‘partially hydrogenated oils’ has taken effect smoothly, with praise from all parties. (Photo by Pornprom Satrabhaya, Bangkok Post)

Thailand’s ban on artificial trans fats came into effect January 9, 2019, making the country the first in Asean to ban the production, import and sale of partially hydrogenated oils, as well as any food that contains them, said the Public Health Ministry.

Derived from plants through the process of hydrogenation, trans fats have been widely used since the 1950s to fry fast foods. Trans fats are also found in margarine and snacks.

Artificial trans fats have been implicated in health problems, such as heart attacks and other cardiovascular conditions.

“The ban [on artificial trans fats] is aimed primarily at reducing the risk of them causing heart disease and other conditions through food consumption,” he said.

The move has garnered praise from World Health Organisation, according to Dr Piyasakol Sakolsatayadorn, Minister of Public Health.

“The WHO praised the government’s political will, as well as the inclusive process that it applied to prepare for the ban,” he said.

“Instead of telling stakeholders what to do, the ministry listened to to all stakeholders and gave them the opportunity to prepare for the transition.”

Dr Piyasakol said the WHO also praised the ministry for launching an effective public campaign to urge the private sector to take part in the government’s bid to ban trans fats, and communicate its importance…

The Public Health Ministry on July 13 published an announcement of the ban in the Royal Gazette. The ban came into effect 180 days from the publication date, which was Wednesday.

Over the past three months, the Food and Drug Administration (FDA) has been working with education institutions and the food industry to help ensure a smooth transition, he said.

Food and beverage produces have already recalled products containing trans fats before the ban took effect, said Dr Tharet Karatnaiyarawiwong, secretary-general of the FDA.

As of Wednesday, food importers are required to issue a certificate assuring that their products are free of the prohibited trans fats, he said.

Source: Bangkok Post –

« Older posts

© 2024 idcOnic Co., Ltd.

Theme by Anders NorenUp ↑